Please note that masks must still be worn within NYOH practices regardless of vaccination status.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

Ph1/2 Ibrutinib+Tras HER2 amp/MBC

Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Disease Types: Breast,&nbs

Available at: {clinical_trial_location backspace="7"}Ph1/2 Ibrutinib+Tras HER2 amp/MBC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}